Estradiol improves cardiovascular function through up-regulation of SOD2 on vascular wall

Redox Biology

Volumn 3, Issue , 2014, Pages 88-99

  Liu, Zhaoyu ^a   Gou, Yulan ^b   Zhang, Hongyu ^c   Zuo, Houjuan ^a   Zhang, Haimou ^d   Liu, Zhengxiang ^a   Yao, Dachun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Department of Neurology ^*  (China)

^c PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^d HUBEI UNIVERSITY   (China)

Author keywords

Endothelium; Estrogen receptor; Gene therapy; Mitochondrial function; Reactive oxygen species

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; ANGIOPOIETIN RECEPTOR; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN BINDING; SUPEROXIDE; TRANSCRIPTION FACTOR SP1;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOTHELIUM CELL; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LENTIVIRINAE; LIPID DIET; MOUSE; NONHUMAN; POSTMENOPAUSE; PROTEIN BINDING; PROTEIN EXPRESSION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BIOLOGICAL MODEL; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; MALE; METABOLISM; MITOCHONDRION; PROMOTER REGION; SEX DIFFERENCE; TRANSFORMED CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; BINDING SITES; CELL LINE, TRANSFORMED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MITOCHONDRIA; MODELS, BIOLOGICAL; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REACTIVE OXYGEN SPECIES; RECEPTOR, TIE-2; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; SEX FACTORS; SP1 TRANSCRIPTION FACTOR; SUPEROXIDE DISMUTASE; SUPEROXIDES; TRANSDUCTION, GENETIC;

EID: 84912072194     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.11.001     Document Type: Article

References (57)

1. Grodstein F., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine 1996, 335(7):453-461. http://www.ncbi.nlm.nih.gov/pubmed/8672166, 10.1056/NEJM199608153350701.
2. Arnal J.F., et al. Estrogens in vascular biology and disease: where do we stand today?. Current Opinion in Lipidology 2007, 18(5):554-560. http://www.ncbi.nlm.nih.gov/pubmed/17885427, 10.1097/MOL.0b013e3282ef3bca.
3. Vina J., et al. Females live longer than males: role of oxidative stress. Current Pharmaceutical Design 2011, 17(36):3959-3965. http://www.ncbi.nlm.nih.gov/pubmed/22188448, 10.2174/138161211798764942.
4. Billon-Galés A., et al. Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. Circulation 2009, 120(25):2567-2576. http://www.ncbi.nlm.nih.gov/pubmed/19996016, 10.1161/CIRCULATIONAHA.109.898445.
5. -/- mice. Journal of Clinical Investigation 2001, 107(3):333-340. http://www.ncbi.nlm.nih.gov/pubmed/11160157, 10.1172/JCI11320.
6. Karas R.H., et al. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proceedings of the National Academy of Sciences of the United States ofAmerica 1999, 96(26):15133-15136. http://www.ncbi.nlm.nih.gov/pubmed/10611350, 10.1073/pnas.96.26.15133.
7. Litwak S.A., et al. Estradiol prevents fat accumulation and overcomes leptin resistance in female high-fat diet mice. Endocrinology 2014, 155(11):4447-4460. 10.1210/en.2014-1342.
8. Rossouw J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Journal of American Medical Association 2007, 297(13):1465-1477. http://www.ncbi.nlm.nih.gov/pubmed/17405972, 10.1001/jama.297.13.1465.
9. Vita J.A., Keaney J.F. Hormone replacement therapy and endothelial function: the exception that proves the rule?. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21(12):1867-1869. http://www.ncbi.nlm.nih.gov/pubmed/11742856.
10. Dubey R.K., et al. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovascular Research 2005, 66(2):295-306. http://www.ncbi.nlm.nih.gov/pubmed/15820198, 10.1016/j.cardiores.2004.12.012.
11. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine 1999, 340(23):1801-1811. http://www.ncbi.nlm.nih.gov/pubmed/10362825, 10.1056/NEJM199906103402306.
12. Kuiper G.G., et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the United States ofAmerica 1996, 93(12):5925-5930. http://www.ncbi.nlm.nih.gov/pubmed/8650195, 10.1073/pnas.93.12.5925.
13. Zhao C., Dahlman-Wright K., Gustafsson J.Å Estrogen signaling via estrogen receptor {beta}. Journal of Biological Chemistry 2010, 285(51):39575-39579. http://www.ncbi.nlm.nih.gov/pubmed/20956532, 10.1074/jbc.R110.180109.
14. Vivar O.I., et al. Estrogen receptor beta binds to and regulates three distinct classes of target genes. Journal of Biological Chemistry 2010, 285(29):22059-22066. http://www.ncbi.nlm.nih.gov/pubmed/20404318, 10.1074/jbc.M110.114116.
15. Park C.J., et al. Genetic rescue of nonclassical ERalpha signaling normalizes energy balance in obese Eralpha-null mutant mice. Journal of Clinical Investigation 2011, 121(2):604-612. http://www.ncbi.nlm.nih.gov/pubmed/21245576, 10.1172/JCI41702.
16. Wu Q., et al. Non-nuclear estrogen receptor signaling in the endothelium. Journal of Biological Chemistry 2011, 286(17):14737-14743. http://www.ncbi.nlm.nih.gov/pubmed/21343284, 10.1074/jbc.R110.191791.
17. O'Lone R., et al. Genomic targets of nuclear estrogen receptors. Molecular Endocrinology 2004, 18(8):1859-1875. http://www.ncbi.nlm.nih.gov/pubmed/15031323, 10.1210/me.2003-0044.
18. Kushner P.J., et al. Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 2000, 74(5):311-317. http://www.ncbi.nlm.nih.gov/pubmed/11162939, 10.1016/S0960-0760(00)00108-4.
19. Delfino F., Walker W.H. Hormonal regulation of the NF-kappaB signaling pathway. Molecular and Cellular Endocrinology 1999, 157(1-2):1-9. http://www.ncbi.nlm.nih.gov/pubmed/10619392.
20. Suzuki A., et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. Journal of Biological Chemistry 2010, 285(18):13444-13453. http://www.ncbi.nlm.nih.gov/pubmed/20200160, 10.1074/jbc.M109.062430.
21. Levonen A.L., et al. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation 2008, 117(16):2142-2150. http://www.ncbi.nlm.nih.gov/pubmed/18427144, 10.1161/CIRCULATIONAHA.107.718585.
22. Ohashi M., et al. MnSOD deficiency increases endothelial dysfunction in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2006, 26(10):2331-2336. http://www.ncbi.nlm.nih.gov/pubmed/16873728, 10.1161/01.ATV.0000238347.77590.c9.
23. El Assar M., Angulo J., Rodríguez-Mañas L. Oxidative stress and vascular inflammation in aging. Free Radical Biology and Medicine 2013, 65:380-401. http://www.ncbi.nlm.nih.gov/pubmed/23851032, 10.1016/j.freeradbiomed.2013.07.003.
24. Zanetti M., et al. Gene transfer of manganese superoxide dismutase reverses vascular dysfunction in the absence but not in the presence of atherosclerotic plaque. Human Gene Therapy 2001, 12(11):1407-1416. http://www.ncbi.nlm.nih.gov/pubmed/11485632, 10.1089/104303401750298562.
25. Bodnar A.G., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279(5349):349-352. http://www.ncbi.nlm.nih.gov/pubmed/9454332, 10.1126/science.279.5349.349.
26. Jiang X.R., et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nature Genetics 1999, 21(1):111-114. http://www.ncbi.nlm.nih.gov/pubmed/9916802, 10.1038/5056.
27. Métivier R., et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115(6):751-763. http://www.ncbi.nlm.nih.gov/pubmed/14675539, 10.1016/S0092-8674(03)00934-6.
28. Yao D., et al. Fatty acid-mediated intracellular iron translocation: a synergistic mechanism of oxidative injury. Free Radical Biology and Medicine 2005, 39(10):1385-1398. http://www.ncbi.nlm.nih.gov/pubmed/16257648, 10.1016/j.freeradbiomed.2005.07.015.
29. Moran A.L., et al. Estradiol replacement reverses ovariectomy-induced muscle contractile and myosin dysfunction in mature female mice. Journal of Applied Physiology 2007, 102(4):1387-1393. http://www.ncbi.nlm.nih.gov/pubmed/17218423, 10.1152/japplphysiol.01305.2006.
30. Takeshita K., et al. Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circulation Research 2007, 100(1):70-78. http://www.ncbi.nlm.nih.gov/pubmed/17158336, 10.1161/01.RES.0000254788.47304.6e.
31. Bossy-Wetzel E., Green D.R. Assays for cytochrome c release from mitochondria during apoptosis. Methods Enzymology 2000, 322:235-242. http://www.ncbi.nlm.nih.gov/pubmed/10914021, 10.1016/S0076-6879(00)22024-7.
32. Yao D., et al. Chemiluminescence detection of superoxide anion release and superoxide dismutase activity: modulation effect of Pulsatilla chinensis. Analytical and Bioanalytical Chemistry 2004, 379(1):171-177. http://www.ncbi.nlm.nih.gov/pubmed/14985908, 10.1007/s00216-004-2527-z.
33. Zhang W., et al. Endothelial cell-specific liver kinase B1 deletion causes endothelial dysfunction and hypertension in mice in vivo. Circulation 2014, 129(13):1428-1439. http://www.ncbi.nlm.nih.gov/pubmed/24637557, 10.1161/CIRCULATIONAHA.113.004146.
34. Glass C.K., Witztum J.L. Atherosclerosis. The road ahead. Cell 2001, 104(4):503-516. http://www.ncbi.nlm.nih.gov/pubmed/11239408, 10.1016/S0092-8674(01)00238-0.
35. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874. http://www.ncbi.nlm.nih.gov/pubmed/12490960, 10.1038/nature01323.
36. Weber C., Zernecke A., Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nature Reviews Immunology 2008, 8(10):802-815. http://www.ncbi.nlm.nih.gov/pubmed/18825131, 10.1038/nri2415.
37. Shwaery G.T., Vita J.A., Keaney J.F. Antioxidant protection of LDL by physiological concentrations of 17 beta-estradiol. Requirement for estradiol modification. Circulation 1997, 95(6):1378-1385. http://www.ncbi.nlm.nih.gov/pubmed/9118503, 10.1161/01.CIR.95.6.1378.
38. Baltgalvis K.A., et al. Estrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle. PLOS One 2010, 5(4):e10164. http://www.ncbi.nlm.nih.gov/pubmed/20405008, 10.1371/journal.pone.0010164.
39. Safe S., Kim K. Nuclear receptor-mediated transactivation through interaction with sp proteins. Progress in Nucleic Acid Research and Molecular Biology 2004, 77:1-36. http://www.ncbi.nlm.nih.gov/pubmed/15196889, 10.1016/S0079-6603(04)77001-4.
40. Lin J., et al. Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation 2009, 120(3):245-254. http://www.ncbi.nlm.nih.gov/pubmed/19581491, 10.1161/CIRCULATIONAHA.109.868729.
41. Foryst-Ludwig A., et al. Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma. PLoS Genetics 2008, 4(6):e1000108. 10.1371/journal.pgen.1000108.
42. Billon-Galés A., et al. The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proceedings of the National Academy of Sciences of the United States ofAmerica 2009, 106(6):2053-2058. http://www.ncbi.nlm.nih.gov/pubmed/19188600, 10.1073/pnas.0808742106.
43. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocrine Reviews 1999, 20(3):358-417. http://www.ncbi.nlm.nih.gov/pubmed/10368776, 10.1210/edrv.20.3.0370.
44. Gutierrez J., et al. Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circulation Research 2006, 99(9):924-932. http://www.ncbi.nlm.nih.gov/pubmed/17068300, 10.1161/01.RES.0000248212.86638.e9.
45. Doughan A.K., Harrison D.G., Dikalov S.I. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circulation Research 2008, 102(4):488-496. http://www.ncbi.nlm.nih.gov/pubmed/18096818, 10.1161/CIRCRESAHA.107.162800.
46. Ballinger S.W., et al. Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circulation Research 2000, 86(9):960-966. http://www.ncbi.nlm.nih.gov/pubmed/10807868, 10.1161/01.RES.86.9.960.
47. Hong J., et al. Differential susceptibility to obesity between male, female and ovariectomized female mice. Nutrition Journal 2009, 8:11. http://www.ncbi.nlm.nih.gov/pubmed/19220919, 10.1186/1475-2891-8-11.
48. Chambliss K.L., Shaul P.W. Estrogen modulation of endothelial nitric oxide synthase. Endocrine Reviews 2002, 23(5):665-686. http://www.ncbi.nlm.nih.gov/pubmed/12372846, 10.1210/er.2001-0045.
49. Guo J., et al. 17beta-estradiol prevents cell death and mitochondrial dysfunction by an estrogen receptor-dependent mechanism in astrocytes after oxygen-glucose deprivation/reperfusion. Free Radical Biology and Medicine 2012, 52(11-12):2151-2160. http://www.ncbi.nlm.nih.gov/pubmed/22554613, 10.1016/j.freeradbiomed.2012.03.005.
50. Xing D., et al. Estrogen and mechanisms of vascular protection. Arteriosclerosis, Thrombosis, and Vascular Biology 2009, 29(3):289-295. http://www.ncbi.nlm.nih.gov/pubmed/19221203, 10.1161/ATVBAHA.108.182279.
51. Esposito K., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. Journal of American Medical Association 2004, 292(12):1440-1446. http://www.ncbi.nlm.nih.gov/pubmed/15383514, 10.1001/jama.292.12.1440.
52. Buettner R., Schölmerich J., Bollheimer L.C. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 2007, 15(4):798-808. http://www.ncbi.nlm.nih.gov/pubmed/17426312, 10.1038/oby.2007.608.
53. Abel E.D., Litwin S.E., Sweeney G. Cardiac remodeling in obesity. Physiological Reviews 2008, 88(2):389-419. http://www.ncbi.nlm.nih.gov/pubmed/18391168, 10.1152/physrev.00017.2007.
54. Noyan-Ashraf M.H., et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 2013, 127(1):74-85. http://www.ncbi.nlm.nih.gov/pubmed/23186644, 10.1161/CIRCULATIONAHA.112.091215.
55. Al Suwaidi J., et al. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. Journal of the American College of Cardiology 2001, 37(6):1523-1528. http://www.ncbi.nlm.nih.gov/pubmed/11345360, 10.1016/S0735-1097(01)01212-8.
56. Bourassa P.A., et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proceedings of the National Academy of Sciences of the United States ofAmerica 1996, 93(19):10022-10027. http://www.ncbi.nlm.nih.gov/pubmed/8816744, 10.1073/pnas.93.19.10022.
57. Must A., et al. The disease burden associated with overweight and obesity. Journal of American Medical Association 1999, 282(16):1523-1529. http://www.ncbi.nlm.nih.gov/pubmed/10546691, 10.1001/jama.282.16.1523.